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Objectives: A phase I pretargeted radioimmunotherapy trial (EudractCT 200800603096) 
was designed in patients with metastatic lung cancer expressing carcinoembryonic 
antigen (CEA) to optimize bispecific antibody and labeled peptide doses, as well as the 
delay between their injections.
Methods: Three cohorts of three patients received the anti-CEA × anti-histamine-succi-
nyl-glycine (HSG)-humanized trivalent bispecific antibody (TF2) and the IMP288 bivalent 
HSG peptide. Patients underwent a pretherapeutic imaging session S1 (44 or 88 nmol/
m2 of TF2 followed by 4.4 nmol/m2, 185 MBq, of 111In-labeled IMP288) and, 1–2 weeks 
later, a therapy session S2 (240 or 480 nmol/m2 of TF2 followed by 24 nmol/m2, 1.1 GBq/
m2, of 177Lu-labeled IMP288). The pretargeting delay was 24 or 48 h. The dose schedule 
was defined based on preclinical TF2 pharmacokinetic (PK) studies, on our previous 
clinical data using the previous anti-CEA-pretargeting system, and on clinical results 
observed in the first patients injected using the same system in Netherlands.
results: TF2 PK was represented by a two-compartment model in which the central 
compartment volume (Vc) was linearly dependent on the patient’s surface area. PK was 
remarkably similar, with a clearance of 0.33 ±  0.03  L/h/m2. 111In- and 177Lu-IMP288 
PK was also well represented by a two-compartment model. IMP288 PK was faster 
(clearance 1.4–3.3 L/h). The Vc was proportional to body surface area, and IMP288 
clearance depended on the molar ratio of injected IMP288 to circulating TF2 at the 
time of IMP288 injection. Modeling of image quantification confirmed the dependence of 
IMP288 kinetics on circulating TF2, but tumor activity PK was variable. Organ-absorbed 
doses were not significantly different in the three cohorts, but the tumor dose was sig-
nificantly higher with the higher molar doses of TF2 (p < 0.002). S1 imaging predicted 
absorbed doses calculated in S2.
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inTrODUCTiOn
Radioimmunotherapy (RAIT) is a molecular targeted therapy 
whereby irradiation from radionuclides is delivered to target 
tumors using monoclonal antibodies (mAb) directed to tumor 
antigens. RIT delivers a heterogeneous low dose-rate irradia-
tion with an efficacy demonstrated in hematological malignan-
cies sensitive to radiation therapy (1). In solid tumors, more 
resistant to radiation and less accessible to large molecules, 
such as mAb, clinical efficacy remains limited and fractionated 
injections, combination of RAIT with chemotherapy, as well as 
pretargeting approaches, are being studied to improve antitu-
mor efficacy (2).
Pretargeted RAIT (pRAIT) was originally designed to 
improve the therapeutic index (tumor-to-normal tissue ratios) 
and to deliver increased absorbed doses to tumors, as compared 
to directly radiolabeled antibodies or antibody fragments (3, 
4). pRAIT may be achieved in several different ways. Here, a 
bispecific mAb (BsmAb) is administered, followed a few days 
later by a radiolabeled bivalent hapten. With this technology, 
the radioactive bivalent hapten binds avidly to the BsmAb 
attached to the cell surface, whereas the nontargeted radioactive 
hapten clears from the circulation through the kidneys. RAIT 
using directly radiolabeled anti-carcinoembryonic antigen 
(CEA) mAb has shown promising clinical results in metastatic 
medullary thyroid carcinoma (MTC) and metastatic colon 
cancer (5, 6), but pretargeting of CEA-expressing tumors has 
demonstrated a more favorable therapeutic index and antitu-
mor efficacy in preclinical MTC and colorectal cancer (CRC) 
models (7, 8) and clinical feasibility in MTC and small-cell 
lung cancer (SCLC) (9, 10). Two phase I clinical trials assessing 
anti-CEA × anti-diethylene-triamine-pentaacetic acid (DTPA)-
indium BsmAb (murine F6 × 734 and chimeric hMN14 × 734 
BsmAb) with 131I-labeled di-DTPA-indium hapten showed 
encouraging therapeutic results in patients with progressive 
metastatic MTC, with a significantly improved overall survival 
for intermediate- and high-risk patients (11). However, murine 
and chimeric BsmAb (human/mouse) used in these studies 
induced in a high rate of immunization and 26% human antihu-
man antibody (HAHA) or human antimouse antibody (HAMA) 
detection, as reported by Salaün et al. (12).
New generation humanized, recombinant, trivalent BsmAb 
(anti-CEA TF2) and histamine-succinyl-glycine (HSG) peptides 
have thus been developed (13). TF2, composed of a humanized 
anti-HSG Fab fragment derived from the 679 anti-HSG mAb 
and two humanized anti-CEA Fab fragments derived from 
the hMN14 mAb (labetuzumab; Immunomedics, Inc.) by the 
dock-and-lock procedure, should reduce immunogenicity 
and facilitate repeated injections (14, 15). Moreover, the HSG 
peptide, IMP288, allows facile and stable labeling with different 
radiometals, such as 177Lu and 90Y, having favorable physical 
features that could improve pRAIT efficacy. However, Schoffelen 
et al. (16) have shown that doses and pretargeting delays must 
be entirely revisited with the dock-and-lock BsmAb because of 
the very different pharmacokinetic (PK) properties of these new 
agents, as compared to the chemically coupled Fab fragments 
used previously (17).
A phase I/II clinical trial was designed to optimize and assess, 
in CEA-expressing lung cancer patients, the new generation 
pretargeting reagents, i.e., the anti-CEA × anti-HSG TF2 BsmAb, 
and the radiolabeled IMP288 HSG peptide. The clinical protocol 
includes two parts: the first part aims at optimizing BsmAb and 
peptide molar doses and administration schedules for pRAIT in 
three cohorts of three patients, using detailed PK and dosimetry 
analyses, and the second part aims at determining the maximum 
tolerated dose of pRAIT using escalated peptide activities and the 
parameters optimized in the first study part. In the two parts of 
the study, the IMP288 peptide is radiolabeled with indium-111 for 
pretherapeutic imaging and lutetium-177 for therapy. Here, we 
report the results of the optimization part of the study, performed 
in three cohorts of patients receiving different doses of BsmAb and 
peptide, the ratio of BsmAb and peptide molar doses being kept 
constant between the imaging and therapy sessions, as suggested 
by Schoffelen et al. (16). A population PK approach was used to 
model the serum kinetics of the BsmAb and of the radiolabeled 
hapten for the two sessions. Whole body (WB) planar scintigra-
phy and single photon emission computed tomography (SPECT) 
Conclusion: The best dosing parameters corresponded to the shorter pretargeting 
delay and to the highest TF2 molar doses. S1 imaging session accurately predicted PK 
as well as absorbed doses of S2, thus potentially allowing for patient selection and dose 
optimization.
Trial registration: ClinicalTrials.gov NCT01221675 (EudractCT 200800603096).
Keywords: lung cancer, radioimmunotherapy, pretargeting, pharmacokinetics, scintigraphy, SPECT, SPECT/CT, 
dosimetry
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; 
BSA, body surface area; BsmAb, bispecific monoclonal antibody(ies); CEA, 
carcinoembryonic antigen; Cl, clearance; CRC, colorectal cancer; CT, computed 
tomography; DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; 
DTPA, diethylene-triamine-pentaacetic acid; EGFR, epidermal growth factor 
receptor; FDG-PET, positron emission computed tomography using 18F-fluoro-
deoxy-glucose; HAHA, human antihuman antibody; HAMA, human antimouse 
antibody; HSG, histamine-succinyl-glycine; mAb, monoclonal antibody(ies); 
MR, molar ratio of injected hapten to the amount of TF2 present in the patients’ 
serum; MTC, medullary thyroid carcinoma; NSCLC, non-small-cell lung cancer; 
PET, positron emission computed tomography; PK, pharmacokinetic(s); pRAIT, 
pretargeted radioimmunotherapy; RAIT, radioimmunotherapy; SCLC, small-cell 
lung cancer; SD, standard deviation; SPECT, single photon emission computed 
tomography; TF2, anti-CEA  ×  anti-HSG bispecific monoclonal antibody; Vc, 
central compartment volume; WB, whole body.
TaBlE 1 | Dosing scheme.
S1: pretherapy imaging session S2: therapy session
TF2 dose Delay (h) 111in-iMP288 TF2 dose Delay (h) 177lu-iMP288
Cohort I 7 mg/m2 48 185 MBq 37.5 mg/m2 48 1.1 GBq/m2
44 nmol/m2 4.4 nmol/m2 240 nmol/m2 24 nmol/m2
Cohort II 14 mg/m2 48 185 MBq 75 mg/m2 48 1.1 GBq/m2
88 nmol/m2 4.4 nmol/m2 480 nmol/m2 24 nmol/m2
Cohort III 14 mg/m2 24 185 MBq 75 mg/m2 24 1.1 GBq/m2
88 nmol/m2 4.4 nmol/m2 480 nmol/m2 24 nmol/m2
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allowed the description of the biodistribution of the radiolabeled 
peptide and quantitative imaging analyses. Dosimetry assess-
ment was performed together with population PK analysis of the 
time–activity curves.
MaTErialS anD METHODS
Patients
The target population was male or female 18 years of age with 
histological diagnosis of CEA-positive lung cancer including
- small-cell lung cancer who are in partial response or who 
failed after at least two lines of standard radiation and/or 
chemotherapy;
- non-small-cell lung cancer (NSCLC) without activating 
mutation of epidermal growth factor receptor (EGFR) gene 
and who failed after at least one line of chemotherapy.
Only patients with CEA serum level ≥10  ng/mL or CEA 
expression by tissues staining, with at least one known tumor site 
detected by computed tomography (CT) and positron emission CT 
using 18F-fluoro-deoxy-glucose (FDG-PET), were eligible for the 
study. All patients had an Eastern Cooperative Oncology Group 
performance ≤2 or Karnofsky performance status ≥60% and a 
minimum life expectancy of 3 months. For entry into the study, 
patients were required to be at least 4 weeks beyond any major 
surgery, external radiotherapy, chemotherapy, immunotherapy, 
or angiogenesis inhibitor therapy. The patients were required to 
have normal levels of transaminases (AST and ALT ≤ 2.5 × the 
upper limit of normal), total bilirubin level ≤30 mmol/L, creati-
nine (≤2.5 × the upper limit of normal), neutrophils ≥1,500/mL, 
and platelets ≥100,000/mL. Pregnant or breast-feeding women 
were excluded, as were premenopausal women not willing to 
practice adequate birth control methods during the study and for 
3 months afterward. Patients with another known type of inter-
current cancer, uncontrolled diabetes, or a psychiatric disorder 
were also excluded.
All patients gave informed written consent in accordance with 
institutional guidelines, including the Declaration of Helsinki. 
The trial was approved by the responsible ethics committee 
and registered at ClinicalTrial.gov NCT01221675 (EudractCT 
200800603096).
investigational Products and labeling
The trivalent TF2-humanized mAb and the IMP288 peptide, 
which bears two HSG groups (hapten) recognized by the 679 mAb 
and one 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid (DOTA) moiety (13, 18), were prepared suitable for human 
use by Immunomedics, Inc. (Morris Plains, NJ, USA). IMP288 
(146 μg/mL in acetate buffer) was labeled with 185 MBq of 111In 
(Mallinckrodt Medical B.V., Petten, Netherlands) for the imaging 
sessions. IMP288 (24 mol/m2) was labeled with 1.1 GBq/m2 of 
177Lu (IDB Radiopharmacy B.V., Baarle-Nassau, Netherlands) 
for the therapy sessions. The radiochemical purity, determined 
using high performance liquid chromatography (Eckert Ziegler, 
Germany) using a C18 column (ACE 15 cm × 3 mm, France) and 
a gradient of trifluoroacetic acid (0.1% in water) and acetonitrile 
was greater than 90% (94.5 ± 2.2%) for 111In-IMP288 and greater 
than 99.0% (99.5 ±  0.4%) for 177Lu-IMP288.  TF2 was diluted 
in 250  mL 0.9% NaCl and administered by i.v. infusion over 
a period of 30–60  min. 111In- or 177Lu-IMP288 was diluted in 
50 mL of 0.9% NaCl in water and administered by i.v. infusion 
over a period of 30 min. Median-specific activities were 24 MBq/
nmol (range 16–30) for 111In-IMP288 and 47 (range 45–53) for 
177Lu-IMP288.
Study Design and Treatment
Three different pretargeting conditions were examined in three 
cohorts of three patients (Table  1). All patients underwent a 
pretherapy imaging session (S1) using TF2 and 111In-labeled 
IMP288 injections before a therapy session (S2). In the first 
cohort (C1), patients received 7  mg/m2 (44  nmol/m2) of TF2 
followed 48  h later by 4.4  nmol/m2 of IMP288 labeled with 
185 MBq of 111In in S1 and 37.5 mg/m2 (240 nmol/m2) of TF2 
followed 48  h later by 24  nmol/m2 of IMP288 labeled with 
1.1 GBq/M2 of 177Lu in S2. Only patients with successful tumor 
targeting in S1 were eligible to participate in S2. In the second 
cohort (C2), TF2 doses were increased from 7 (44 nmol/m2) to 
14 mg/m2 (88 nmol/m2) in S1 and from 37.5 (240 nmol/m2) to 
75  mg/m2 (480  nmol/m2) in S2, whereas IMP doses, 111In and 
177Lu activities, and the pretargeting delay remained identical 
that in C1. In the third cohort (C3), patients received the same 
TF2 and IMP doses and the same 111In and 177Lu activities than in 
C2 but with a lower pretargeting interval (24H instead of 48H). 
For each cohort of patients, TF2 and IMP288 were administered 
using the same pretargeting interval and the sameTF2/IMP288 
molar ratio in S1 and S2.
Six French centers were allowed to include and treat patients 
in this multicentric study: Nantes University Hospital Nuclear 
Medicine Department, Nantes ICO Cancer Centre Nuclear 
Medicine Department, Brest University Hospital  Nuclear 
Medicine Department, Angers University Hospital 
TaBlE 3 | Characteristics of patients.
Median age 65 (53–80)
Male/female 7/2
Histological type 6 SCLC/3 NSCLC
Karnofsky index
90–100 5
70–80 2
60–70 2
Median CEA plasma level (min–max) 79 ng/mL (10–388)
Prior treatment
 Chemotherapy 100%
 Radiotherapy 67%
 Surgery 33%
 Tyrosine kinase inhibitors 11%
Site of disease
 Lung 78%
 Mediastinum 78%
 Liver 56%
 Pancreas 22%
 Adrenal 33%
 Infradiaphragmatic nodes 33%
 Bone 11%
 Muscle 11%
 Brain 11%
Median delay from initial diagnosis (min–max) 25 months (10–64)
TaBlE 2 | 111in and 177lu system sensitivities for both types of gamma 
cameras in all centers.
System sensitivity (counts/MBq s)
Crystal thickness 111In 177Lu
3/8″ 170 ± 2 15 ± 2
5/8″ 230 ± 2 18 ± 2
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Nuclear  Medicine Department, Clermont-Ferrand University 
Hospital Nuclear Medicine department, and Grenoble University 
Hospital Nuclear Medicine Department.
Safety was assessed during infusions by monitoring vital 
signs, physical examination, and adverse events. Patients were 
premedicated with antihistamine (xyzall®) and corticosteroid 
(intravenous dexamethasone) before each TF2 and peptide 
infusion.
NCI Common Toxicity Criteria Version 3.0 were used to 
evaluate toxicity. Total WBC and lymphocytes were monitored 
and reported every week until 8 weeks post-177Lu-IMP288 injec-
tion or until platelet (>100 g/L without transfusion), hemoglobin 
(>10 g/dl without transfusion), and leukocyte (>2 g/L) recovery. 
Assessment of hematological toxicity was only based on hemo-
globin level (Hgb), absolute neutrophil counts, and platelet 
counts. Biochemical tests including serum creatinine, creatinine 
clearance, AST, ALT, total bilirubin, alkaline phosphatase, 
calcium, phosphorus, uric acid, sodium, potassium, and serum 
electrophoresis were performed 4 weeks, 8 weeks, and then every 
3 months after pRAIT.
Assessment of response was based on physical examination, 
CEA serum level, CT and FDG-PET performed 4  weeks after 
pRAIT, at 3 months, and then every 3 months until progression. 
Responses were scored according to the Response Evaluation 
Criteria in Solid Tumors (RECIST 1.0) (19).
Human antihuman antibody was determined within 2 days of 
the second TF2 infusion, then 4 weeks, 8 weeks, and 3 months 
after the last TF2 infusion using an ELISA method. The detection 
limit for positive HAHA was 50 ng/mL.
Pharmacokinetics
Blood samples were collected in separator tubes for serum 
collection at the following times after TF2 injection and after 
administration of 111In-IMP288 or 177Lu-IMP288: before the 
beginning of the infusion, 5 min before the end of the infusion, 
then 5 min, 1 h, 2–4 h, 24 h, and then at four other times over 
7 days. Blood samples were collected for all patients during S1 
and S2. Serum samples (at least 1 mL) were prepared from blood 
samples and stored frozen. TF2 concentrations were determined 
using an ELISA (Immunomedics), as described previously (18). 
The indium-111 or lutetium-177 activity in each serum sample 
was determined by counting 0.1–0.2 mL of serum in a calibrated 
gamma counter. Counting was performed immediately after the 
end of each blood collection series and corrected for radioactive 
decay.
Modeling of the serum concentration PK was performed 
using a two-compartment model for the bispecific antibody 
(TF2) and two or three compartment models for the radiolabeled 
hapten (IMP288), using a population PK software package, 
developed in the laboratory and validated against Monolix (20). 
Patients’ body surface areas (BSAs) were used as covariables. 
In the hapten PK analyses, several covariables were tested to 
represent the effect of TF2 on the kinetics of IMP288. Finally, 
the molar ratio of injected hapten to the amount of TF2 present 
in the patients’ serum (MR), calculated as the concentration of 
TF2 extrapolated to the time of hapten injection multiplied by 
the central compartment volume (Vc) obtained in the TF2 PK 
analysis, was the covariable used to take the effect of TF2 on 
IMP288 PK into account. Since the addition of a third compart-
ment did not improve data fitting, two-compartment models 
were used. Parameters for the two-compartment model of 
serum kinetics for both TF2 and IMP288 were the transfer rates 
(k2,1 and k1,2), the elimination rate (kel), and the Vc per BSA unit 
(volume/m2). The Vc was a dependent parameter (Vc = volume/
m2 × patient BSA). For the serum IMP288 PK, clearance was 
calculated as As  ×  MRBS, MR being the ratio of the number 
of moles of injected IMP288 to the number of moles of TF2 
present in the circulation at the time of IMP288 injection, AS 
and BS being two adjustable parameters, and kel was calculated 
as clearance/Vc.
For the WB IMP288 kinetics, the activity calculated from WB 
images was modeled as the sum of the central and distribution 
compartments with adjustable transfer rates (k2,1 and k1,2) and two 
additional adjustable parameters, AWB ad BWB, used to calculate 
the elimination rate: k A MRel WB
BWB= × .
For the PK analysis of tissue distribution from image quantifica-
tion, the WB kinetics was used as an input function, and the IMP288 
distribution in tissues of interest was modeled using a tissue-specific 
distribution compartment and a fraction of the activity in the cen-
tral compartment. The on and off rate constants, kon and koff, and the 
fraction of activity (fraction) were adjustable parameters.
FiGUrE 1 | Pharmacokinetics of the bispecific antibody TF2. Each patient received two infusions of TF2 at 7 or 8 days intervals (except patient 5). Blood 
samples were collected at selected time intervals during and after each infusion and centrifuges. TF2 concentrations were measured using a specific ELISA. The 
pharmacokinetics was then modeled using a two-compartment model and a population approach. Data collected after both infusions were fitted using a single set 
of parameters. Results (open squares) are plotted as a semilog plot with the population (dashed lines) and individual (solid lines) fitted curves.
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TaBlE 4 | Two-compartment population analysis of TF2 pharmacokinetics.
Parametera k2,1 (h−1) k1,2 (h−1) kel (h−1) Volume/m2 (l/m2) Vc (l) Clearance (l/h)
Population values
Estimation 0.034 0.0075 0.182 1.86 NA NA
SD 0.002 0.0005 0.003 0.04 NA NA
individual values
Patient 1 0.033 0.0062 0.194 2.00 4.01 0.78
Patient 2 0.033 0.0080 0.177 1.82 2.71 0.48
Patient 3 0.036 0.0081 0.169 1.83 4.93 0.84
Patient 4 0.036 0.0071 0.182 1.80 3.33 0.61
Patient 5 0.034 0.0075 0.1.83 1.81 3.05 0.56
Patient 6 0.033 0.0085 0.174 1.84 3.20 0.56
Patient 7 0.035 0.0068 0.183 1.92 3.73 0.68
Patient 8 0.035 0.0073 0.177 1.77 3.45 0.61
Meanb 0.034 0.074 0.180 1.85 3.52 0.64
SD 0.001 0.001 0.007 0.07 0.69 0.12
CV (%) 5.5 14.5 9.0 7.7 21.4 20.1
aThe transfer rates (k2,1 and k1,2), the elimination rate (kel), and the central compartment volume per body surface area unit (m2) were adjusted to a two-compartment model. The 
central compartment volume was a dependent parameter (Vc = volume/m2 × patient body surface area) as well as clearance (clearance = Vc × kel).
bThe mean, SD, and CV for each parameter were calculated from individual estimations. Note the low interindividual variability and the lower CV of the adjusted volume per square 
meter compared to that of the actual central compartment volumes (Vc).
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Scintigraphy
All imaging centers were equipped with the same model of 
SPECT/CT gamma-camera (Symbia T/T2, Siemens). For 
pretherapeutic and therapeutic imaging sessions, three to five 
images were scheduled from 1 h to 7 days after radiopharma-
ceutic injection depending on the patient’s ability to sustain 
imaging procedures. Each imaging session consisted of WB 
emission scan (256 × 1,024 pixels) and tomographic acquisitions 
(128 × 128 pixels, 2 × 32 projections, and 30–45 s per projec-
tion). Each scans or tomographic acquisitions were performed 
using medium energy collimators. Due to expected low level of 
detected counts, especially at late time points, energy windows 
were centered on the two major peaks (15% width). In order to 
correct for Compton scattering (21), two energy windows (4% 
width) adjacent to each main peak were simultaneously acquired. 
CT scans (120 kVp, 100 mAs) were acquired in order to derive 
CT attenuation maps. Tomographic procedures consisted of two 
acquisitions to cover patients from lungs to pelvic area.
At an initial stage, as involved centers were equipped with thin 
(3/8″) or thick (5/8″) crystals, system planar sensitivity was evalu-
ated for these two types of equipment for 111In and 177Lu sources 
of known activity (~200 and 900 MBq, respectively) poured in 
a thin cylinder plate (Table 2). As tomographic reconstructions 
accounted for point response function of the collimator, this fea-
ture was characterized by the full width of half-maximum of point 
source images at different distances from collimator plate. Gamma 
cameras and dose calibrator quality controls were performed in 
accordance to each institution procedures (no crosscalibration). 
Particular attention was given to patient alignment for each imag-
ing session to help image registration during processing.
Dosimetry
Quantitative imaging was performed on tomographic recon-
structions (OSEM 30 iterations, eight subsets) taking into 
account attenuation, Compton scattering (correction performed 
on projections), and collimator response corrections as expressed 
in international guidelines (22). Initial estimated system sensitiv-
ity reported in Table 2 was used to translate detected count into 
activity for 111In and 177Lu acquisitions.
Patients’ organ masses were derived from automatic or manual 
CT images segmentation performed with 3D Slicer (23) software. 
Trabecular bones in L2–L4 lumbar vertebras were also segmented 
in order to evaluate bone marrow-absorbed dose (24). Tumor 
volumes were segmented on emission-reconstructed images and 
performed on images where the tumor-to-background ratio was 
visually designed as optimum. Tumor labeled volumes were sub-
sequently exported as DICOM-RT structure set and integrated 
into the patient labeled-organs images after registration.
In order to obtain time–activity curves for volumes of interest, 
labeled images were registered against CT images performed at 
every imaging session using the MedInria software (25). Then, 
organ time–activity curves were adjusted with nls package of R 
software (26) using mono- or biexponential functions depending 
on the number of time points available to perform the regression 
analysis and submitted to a population PK analysis using the 
laboratory software package.
To estimate patient’s organ-absorbed doses at pretherapeutic 
and therapeutic stages, MIRD S factors were scaled by patient 
organ masses. Time integration of fitted functions was calculated 
to derive cumulated activities at both sessions. Estimations at 
pretherapeutic were scaled to take into account the difference 
between physical half-lives of both radionuclides.
Statistics
Organ effective periods estimated at S1 and S2, as well as tumor- 
and organ-absorbed doses for each schedule, were compared 
using the Wilcoxon statistical test.
For each patient, Spearman statistical tests were conducted 
to evaluate whether S1-absorbed doses were able to predict 
absorbed doses during S2.
FiGUrE 2 | Pharmacokinetics of the labeled hapten iMP288. 
(Continued)
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rESUlTS
Patient Characteristics and Therapy 
results
Ten patients were included in the study between June 2011 and 
September 2014 (one patient included in Brest, two patients in 
Angers, two patients in Nantes University Hospital, and five 
patients in Nantes ICO Cancer Centre) and nine were treated; 
one on the five patients included in Nantes ICO Cancer Centre 
died between the inclusion and the beginning of the study. 
Characteristics of the nine treated patients are summarized in 
Table 3. All patients received 185 MBq of 111In-IMP288 for the 
pretherapeutic session S1 and a median activity of 2,147  MBq 
(1,641–3,026 MBq) of 177Lu-IMP288 for the therapeutic session 
S2, one or 2 weeks later. None of the nine patients experienced an 
anaphylactic reaction during TF2 or peptide infusion. One patient 
died 5 days after pRAIT (not considered treatment related) and 
was not evaluable for PK analysis, dosimetry, toxicity, or response 
assessment.
Bone marrow toxicity was mild in most patients (grade 1 
thrombocytopenia in 2/9 patients). Only one patient experienced 
grade 2 anemia 3 months after 177Lu administration. Three patients 
with liver metastases showed transaminase enzymes (AST and 
ALT) elevation during the follow-up, which was deemed to be 
disease-related, since the three patients had progression of liver 
metastases on CT and FDG-PET registered 4 weeks after pRAIT. 
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FiGUrE 2 | Continued 
Each patient received TF2 infusions then 24 or 48 h after each infusion, they received an infusion of IMP288 labeled with indium-111 after the first TF2 infusion or 
labeled with lutetium-177 after the second. Blood samples were collected at selected time intervals during and after each infusion, centrifuged, and counted. 
Indium-111 counts were corrected to match lutetium-177 radioactive half-life, and the figure shows IMP288 activity concentrations. The pharmacokinetics was 
modeled using a two-compartment model and a population approach. Results (open squares) are plotted as a semilog plot with the population (dashed lines) and 
individual (solid lines) fitted curves.
None of the patients showed biological signs or symptoms of 
renal toxicity.
According to RECIST criteria based on FDG-PET and CT data, 
two patients were considered as stable at 4 weeks post-pRAIT but 
progressive at 3 months. The six others patients were progressive 
as soon as 4 weeks after pRAIT.
Human antihuman antibody elevation was detected in 1/8 
patients, 1  month after the second TF2 infusion, gradually 
decreasing from 2,966  ng/mL at 4  weeks to 969  ng/mL in the 
follow-up period of 3 months.
TF2 Pharmacokinetics
Simultaneous modeling of the two TF2 infusions for the eight 
patients who completed both S1 and S2 sessions using a two-
compartment model showed that the PK was consistent between 
the two infusions, even if they were given at different TF2 molar 
doses (Figure 1). The use of population PK and the simultane-
ous modeling of the S1 and S2 TF2 infusions surmounted the 
problem of the limited sensitivity of the ELISA (Table  4). The 
small differences observed between the population and the 
individual fits showed that interindividual variability was quite 
TaBlE 5 | Two-compartment population analysis of iMP288 pharmacokinetics.
Parametera k2,1 (h−1) k1,2 (h−1) AS BS Mr kel (h−1) Volume/m2 
(l/m2)
Vc (l) Clearance 
(l/h)
Population values
Estimation 0.027 0.019 1.42 0.182 NA NA 6.38 NA NA
SD 0.001 0.002 0.07 0.012 NA NA 0.27 NA NA
individual values
Patient 1, indium 0.027 0.021 1.35 0.169 124.2 0.226 6.69 13.4 3.04
Patient 1, lutetium 0.024 0.021 1.37 0.172 125.5 0.241 6.50 13.1 3.15
Patient 2, indium 0.026 0.023 1.31 0.167 40.7 0.250 6.54 9.7 2.43
Patient 2, lutetium 0.027 0.022 1.22 0.156 40.1 0.219 6.63 9.9 2.16
Patient 3, indium 0.028 0.015 1.53 0.199 35.7 0.185 6.23 16.8 3.11
Patient 3, lutetium 0.028 0.017 1.43 0.183 37.8 0.165 6.25 16.8 2.78
Patient 4, indium 0.026 0.026 0.92 0.141 22.6 0.112 6.90 12.7 1.43
Patient 4, lutetium 0.029 0.019 1.29 0.167 22.0 0.173 6.78 12.5 2.17
Patient 5, indium 0.027 0.017 1.53 0.196 22.5 0.235 6.15 12.0 2.82
Patient 5, lutetium 0.028 0.017 1.52 0.196 31.1 0.249 6.13 11.9 2.97
Patient 6, indium 0.027 0.019 1.41 0.179 109.0 0.291 6.44 11.2 3.25
Patient 6, lutetium 0.028 0.021 1.31 0.170 18.8 0.179 6.93 12.0 2.15
Patient 7, indium 0.027 0.022 1.41 0.181 3.3 0.146 6.21 12.0 1.76
Patient 7, lutetium 0.028 0.018 1.41 0.181 3.2 0.137 6.54 12.7 1.74
Patient 8, indium 0.028 0.018 1.44 0.182 2.3 0.161 6.18 10.4 1.68
Patient 8, lutetium 0.028 0.020 1.16 0.174 2.5 0.124 6.49 10.9 1.36
Meanb 0.027 0.020 1.35 0.176 0.193 6.47 12.4 2.37
SD 0.001 0.003 0.16 0.015 0.052 0.27 2.0 0.65
CV (%) 4.5 14.3 11.5 8.6 27.0 4.1 16.4 27.5
aThe transfer rates (k2,1 and k1,2), the central compartment volume per body surface area unit (m2), and the two parameters A and B were adjusted using a two-compartment 
model. Estimations of the population adjusted parameters are given together with their estimated SD. The central compartment volume was a dependent parameter (Vc = volume/
m2 × patient body surface area). Clearance was calculated as AS × MRBS, MR being the ratio of the number of moles of injected IMP288 to the number of moles of TF2 present in 
the circulation at the time of IMP288 injection and the elimination constant kel as clearance/Vc.
bThe mean, SD, and CV for each parameters were calculated from individual estimations.
FiGUrE 3 | Whole body and SPECT/CT images of patient 1 (cohort i). Whole body and SPECT/CT images were acquired 24 and 48 h after injection of 
111In-labeled IMP288 (a,C) and 177Lu-labeled IMP288 (B,D). Patient 1 included in the first cohort had SCLC and a CEA level of 79 ng/mL. These images showed low 
tumor targeting in liver, mediastinum, and lung metastases.
November 2015 | Volume 2 | Article 849
Bodet-Milin et al.  Pretargeted Radioimmunotherapy in CEA-Expressing Lung Cancer
Frontiers in Medicine | www.frontiersin.org
FiGUrE 4 | Whole body and SPECT/CT images of patient 4 (cohort ii). Whole body images (anterior view) were acquired 4, 24, 48, and 72 h after injection of 
111In-labelled IMP288 (a) and 177Lu-labelled IMP288 (B). Patient 4, included in the cohort II, had NSCL and a CEA level of 275 ng/mL. These images clearly shows 
lung tumor targeting in whole body and SPECT/CT images [(C) with 111In-labelled IMP288 and (D) with 177Lu-labelled IMP288]. According to RECIST criteria, the 
disease was considered as stable at 4 weeks, but progressive at 3 months. Patient 4 was the only patient with HAHA against TF2 > 50 ng/mL detected 1 month 
after the last TF2 injection.
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small. The serum kinetics was rather fast with mean alpha half-
lives of 3.7 ± 0.1 h and beta half-lives of 21.3 ± 0.7 h, with very 
low interindividual variability (3.2 and 3.3%, respectively). Mean 
serum clearance was 0.64 ±  0.12 L/h, and the use of BSA as a 
covariable (by setting Vc = VBA × BSA) reduced the coefficient 
of variation of the Vc from 19 to 4.0% for the estimated parameter 
(VBA). This observation validates a posteriori the dosing scheme 
of the dose escalation on a BSA basis (44/88 nmol/m2 for S1 and 
240/480 nmol/m2 for S2).
iMP288 Pharmacokinetics
Modeling the kinetics of the hapten was complicated by the 
necessity to take into account the effect of the residual bispecific 
antibody in serum at the time of hapten administration, which 
binds the hapten and modulates its clearance. To compare the 
PK of IMP288 labeled with indium-111 and with lutetium-177, 
indium activities were corrected for radioactive decay and trans-
formed into equivalent lutetium-177 counts, assuming similar 
PK for IMP288 labeled with the two radionuclides (16). Then, 
the time–activity curves were fitted individually for all patients 
to a two-compartment model, which gave a good visual fit, not 
significantly improved by a third compartment according to the 
Akaike criterion (not shown). In a second step, the relationship 
between IMP288 PK and the pretargeting conditions was tested 
by plotting the estimated clearance or the Vc against the con-
centration of TF2 at the time of IMP288 injection (interpolated 
from the fitted TF2 concentration curves), or the amount of TF2 
present in the circulation at the time of IMP288 (calculated as 
TF2 concentration  ×  TF2 Vc), or the molar ratio of injected 
IMP288 to the amount of TF2 in the circulation (MR). Indeed, 
in the circulation, TF2 binds the IMP288 hapten and slows its 
clearance. It seems logical that the lower the excess of IMP288 
relative to TF2, the larger the trapping of IMP288 in the circula-
tion by the bispecific antibody, and hence, the slower its clearance. 
The correlation based on a power relationship was found to be 
better between clearance and MR, which was used thereafter as a 
covariable in the population analysis.
A population PK analysis was then performed on all 16 
available kinetics, using BSA and MR as covariables. The larger 
interindividual variability in the IMP288 than in TF2 kinetics, 
with mean alpha half-lives of 3.4 ± 0.8 h and beta half-lives of 
28.9 ± 2.1 h (corresponding to CV of 24 and 7.3%, respectively), 
could be explained in part by the influence of TF2 predose. 
The IMP288-indium-111 kinetics for patient 4 appeared as an 
outlier (Figure 2) but was not excluded from the analysis. The 
PK of the hapten is known to depend on the presence of TF2 in 
body fluids, and a strong correlation had been described earlier 
between IMP288 blood residence time and the concentration of 
TF2 blood concentrations at the time of peptide injection (16). 
Since the individual fitting analysis pointed to a relationship 
between hapten clearance and MR, MR was introduced in the 
population analysis as a covariable, and IMP288 clearance was 
calculated as CI A MRB
BB= ×  and kel as clearance/Vc (Table 5). 
Parameter adjustment finally gave clearance (L/h) = 1.33 × MR0.18 
(R2 = 0.66). As expected, IMP288 clearance was higher than that 
of TF2, varying from 1.36 to 3.25 L/h, depending on MR, thus on 
the pretargeting conditions.
Since IMP288 kinetics were primarily driven by MR, and given 
the low interindividual variability of TF2 kinetics, pretargeting 
parameters (i.e., molar injected doses of TF2 and IMP288 and pre-
targeting delay) are expected to control the hapten kinetics. This 
means that the kinetics of the therapeutic session may be predicted 
TaBlE 6 | Two-compartment population analysis of whole body iMP288 activity pharmacokinetics.
Parametera k2,1 (h−1) k1,2 (h−1) AWB BWB Mr kel (h−1)
Population values
Estimation 0.0163 0.0096 0.105 0.14 NA NA
SD 0.0014 0.0009 0.004 0.01 NA NA
individual values
Patient 1, indium 0.0152 0.0101 0.097 0.13 124.2 0.18
Patient 1, lutetium 0.0177 0.0094 0.110 0.15 125.5 0.23
Patient 2, indium 0.0126 0.0100 0.104 0.14 40.7 0.18
Patient 2, lutetium 0.0138 0.0101 0.115 0.16 40.1 0.21
Patient 3, indium 0.0178 0.0090 0.115 0.16 35.7 0.20
Patient 3, lutetium 0.0197 0.0085 0.121 0.17 37.8 0.23
Patient 4, indium 0.0136 0.0099 0.097 0.14 22.6 0.15
Patient 4, lutetium 0.0166 0.0099 0.089 0.13 22.0 0.13
Patient 5, indium 0.0146 0.0104 0.098 0.14 22.5 0.15
Patient 5, lutetium 0.0165 0.0102 0.083 0.12 31.1 0.13
Patient 6, indium 0.0141 0.0101 0.071 0.11 109.0 0.12
Patient 6, lutetium 0.0166 0.0098 0.091 0.13 18.8 0.13
Patient 7, indium 0.0143 0.0101 0.102 0.14 3.3 0.12
Patient 7, lutetium 0.0191 0.0090 0.070 0.13 3.2 0.08
Patient 8, indium 0.0141 0.0100 0.110 0.15 2.3 0.12
Patient 8, lutetium 0.0190 0.0090 0.098 0.14 2.5 0.11
Meanb 0.0160 0.0097 0.098 0.14 0.15
SD 0.0022 0.0006 0.015 0.02 0.04
CV (%) 13.9 5.8 15.2 11.6 29.0
aWhole body (WB) activity kinetics was modeled as the sum of the activities in a central compartment and a distribution compartment with transfer rates (k2,1 and k1,2), and two 
parameters A and B as adjustable parameters; the elimination constant kel was calculated as , MR being the ratio of the number of moles of injected IMP288 to the number of moles 
of TF2 present in the circulation at the time of IMP288 injection. Estimations of the population adjusted parameters are given together with their estimated SD.
bThe mean, SD, and CV for each parameter were calculated from individual estimations.
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by the imaging session, in spite of the fact that absolute molar doses 
of the reagents are different, which will be confirmed hereafter.
Scintigraphy and Quantitative analyses
Images registered after 111In-labeled IMP288 showed targeting of 
all known tumors in all patients. WB scintigraphy and SPECT/
CT images recorded after S1 and S2 were concordant (example 
of patients included in C1 and C2 are shown in Figures 3 and 4) 
even if tumor targeting visually appeared to be better in S2 than 
in S1 images, due to the higher levels of administered activity.
Reconstructed tomographic images were quantified and 
indium-111 counts were also corrected for radioactive decay to 
allow for comparison with the lutetium-177 data. A two-com-
partment model was used to describe the kinetics of WB counts 
(Table 6). The mean alpha half-life was 4.3 ± 1.1 h and beta half-
life 80 ± 7 h, corresponding to a relatively large interindividual 
variability (25 and 9%, respectively).
The activity in the organs was modeled by a fraction of the 
activity in the central compartment plus an organ-specific dis-
tribution compartment, as described in the literature (27). Then 
the kinetics of activities in all regions of interest (WB, right and 
left lungs, liver, right and left kidneys, spleen, heart, whole aorta, 
and tumor), for all eight patients and for the two sessions, was 
fitted simultaneously by a population analysis. As in the serum 
kinetics analysis, the rate constant of elimination (kel) from the 
central compartment was set as a power function of MR, and tis-
sue weights were introduced in the analysis. A reasonable fit was 
obtained, except for tumors, for which variations in on rates and 
off rates were too large to consider a population PK analysis and 
were thus adjusted individually. This analysis demonstrated the 
consistence of the measured activities and a relationship between 
WB clearance, and MR was again observed [kel (1/h) =  0.095 
MR0.15], but with a lower correlation coefficient (R2 = 0.45) than 
in the serum count analysis.
This analysis showed that tissue uptake, on an organ weight 
basis, as assessed by the organ compartment volume, was higher 
in kidneys and liver, as expected, intermediate in lungs and spleen, 
and lower in aorta and heart, whereas the fractions of activity in 
fast equilibrium with the central compartment was similar in all 
tissues, including tumors (Table 7). Tumor uptake was variable 
and higher in patients 4, 5, 6 (C1), and 7 (C2).
Dosimetry
The PK modeling of image data was completed by a classical 
dosimetry study performed as described in Section “Materials and 
Methods.” Figures 5 and 6 present organ-absorbed doses normal-
ized by injected activity estimated at S1 and S2. Considering cohort 
categorization, no significant differences in organ-absorbed 
doses estimated from both sessions were observed, as shown by 
Wilcoxon tests (p > 0.05). At the patient level, normalized organ-
absorbed doses at S1 were also compared against those estimated 
at S2, using the Spearman test. Spearman’s rho and corresponding 
p-value are reported in Table 8 and showed a good correlation 
between organs-absorbed doses estimated at both sessions.
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For all patients, 24 tumors were delineated on reconstructed 
SPECT or CT images. They were mostly located in lungs (37%) 
and liver (29%). Median tumor mass was 19.3 g (1.1–1,364 g). 
Median normalized tumor-absorbed doses in the three cohorts 
ranged from 0.05 to 0.25  mGy/MBq in S1 and from 0.10 to 
0.54  mGy/MBq in S2. Extreme normalized tumor-absorbed 
doses for each cohort ranged from 0.02 to 0.12 mGy/MBq in S1 
and from 0.52 to 1.08  mGy/MBq in S2. These absorbed doses 
not appeared to be significantly different as shown by a Wilcoxon 
test conducted on previous values (p >  0.13). Nevertheless, a 
Spearman test conducted on previous data showed a good cor-
relation (rho = 0.85, p < 10−15) between tumor-absorbed doses 
estimated at both sessions.
Kruskal–Wallis tests were performed to compare organ-
absorbed doses at each different dosage level and for both 
sessions. Statistical tests did not exhibit significant difference 
between groups for organs (p >  0.07). The same analysis was 
conducted on tumor-absorbed doses and showed significantly 
higher tumor-absorbed doses in patients included in cohort II or 
III than in cohort I (p < 0.002) as illustrated by Figure 6.
DiSCUSSiOn
The main objectives of this study were to assess whether an 
imaging session may be predictive of absorbed doses in therapy 
(IMP288 labeled with indium-111 in the imaging session and 
with lutetium-177 in the therapy session) and to find the best 
pretargeting parameters (molar doses of TF2 and IMP288 and 
pretargeting delay) for cancer therapy. The imaging sessions were 
performed using molar doses 5.4 times lower than in the therapy 
session, to reduce exposure of the patients to the pretargeting 
reagents. This was assumed feasible without compromising the 
predictive character of the imaging session, based on the earlier 
preclinical assessment of the compounds and in view of the results 
obtained by Schoffelen et al. (16). It was, however, important to 
confirm this result in a different clinical setting.
To this end, PK modeling of TF2 serum concentration kinetics, 
IMP288 serum activity kinetics (adjusted to the physical half-life 
of lutetium-177 to allow comparisons), and of IMP288 activities 
measured by SPECT in WB and regions of interest corresponding 
to major tissues and tumors was performed using a population PK 
modeling software developed in our laboratory (available upon 
request) that allowed for simultaneous multicompartment and 
multitissue analyses. The population approach allowed a more 
consistent modeling of data, ensuring convergence of parameter 
estimations even in cases where the number of data points was 
small due to assay sensitivity (TF2) or number of imaging ses-
sions. In addition, the population approach allowed us to confirm 
that calculating individual TF2 or hapten doses on the basis of 
BSA reduced the variability of circulating TF2 concentrations 
and also allowed us to define a relationship between circulating 
TF2 concentrations at the time of hapten administration and 
the kinetics of the hapten. This relationship is complex, but it is 
expected that TF2 binds the hapten in the circulation and slows 
down its clearance, as already observed in many preclinical 
studies and in earlier clinical studies with chemically coupled 
bispecific antibodies (17).
The population PK analyses showed that molar ratios and 
time intervals must be kept constant, but that there is no need to 
perform the imaging and therapy sessions with the same molar 
doses, in order to obtain comparable hapten serum and tissue 
uptake kinetics in both imaging and therapy sessions. Indeed, 
quantitative assessment of the images showed that not only the 
serum kinetics, but also the distribution of activity in normal tis-
sues and tumors in the therapy session may be predicted from the 
imaging session, as shown by the very high degree of correlation 
obtained. Being able to predict dosimetry, and avoiding treatment 
of patients whose tumor lesions do not bind the activity, using a 
low dose, pretherapy, imaging session, according to the theranos-
tic approach, is a significant advantage in clinical practice.
The very different PK behavior of TF2 as compared to chemi-
cally coupled BsmAb requires pretargeting optimization studies. 
The pretargeting parameters must be finely tuned to avoid high 
circulating activities, detrimental to normal tissue dosimetry in 
therapy, and background in imaging, while keeping tumor uptake 
as high as possible. In this study, in spite of the small number 
of patients in each cohort, some conclusions can be drawn. In 
cohort I, comparatively low doses of TF2 were administered 
(7 and 37.5  mg/m2) with a delay of 48  h. This results in a fast 
clearance of the hapten and a low tumor uptake. In cohort II, 
the higher doses of TF2 (14 and 75  mg/m2) resulted in slower 
clearance of activity and significantly increased tumor uptake. 
Reduction of the delay to 24 h further increased the amount of 
TF2 present in the circulation and tissues at the time of hapten 
injection but did not significantly increased tumor uptake over 
cohort III, probably because of the high observed variability and 
because lutetium-177 data were available for only two patients.
Although serum and organ PK showed a correlation between 
MR and clearance, it must be noted that between cohort I and 
cohort III, clearance is only reduced by a factor of approximately 
two. In contrast, a significant difference in tumor-absorbed 
doses is found between cohort I and cohorts II and III, showing 
that increase of the TF2 dose and reduction of the pretargeting 
delay had a positive impact on tumor uptake without increasing 
significantly the doses delivered to normal tissues.
In line with the dosimetry assessment, hematological toxicity 
was quite limited, and non-hematological toxicity was observed 
only in liver involved with tumor in three cases. To further increase 
TaBlE 7 | Population analysis of iMP288 activity distribution.
Parametera kon (1/h × 103) koff (1/h × 102) Fraction (l/kg × 102)
Lung 1.06 ± 0.06 1.17 ± 0.06 3.38 ± 0.19
Liver 1.45 ± 0.11 1.14 ± 0.08 2.33 ± 0.21
Kidneys 4.35 ± 0.28 2.22 ± 0.08 5.91 ± 0.37
Spleen 1.48 ± 0.11 1.30 ± 0.08 2.21 ± 0.19
Heart 0.45 ± 0.04 0.94 ± 0.09 3.08 ± 0.21
Aorta 0.61 ± 0.05 1.04 ± 0.09 3.66 ± 0.26
Tumor 2.70 ± 0.26
aIMP288 distribution in tissues of interest was modeled using a tissue-specific 
distribution compartment and a fraction of the activity in the central compartment; 
the on and off rate constants, kon and koff, and the fraction of activity (fraction) were 
adjustable parameters using the central compartment of the whole body kinetics as the 
input function.
November 2015 | Volume 2 | Article 8413
Bodet-Milin et al.  Pretargeted Radioimmunotherapy in CEA-Expressing Lung Cancer
Frontiers in Medicine | www.frontiersin.org
tumor-absorbed doses, the shorter pretargeting delay of 24 h thus 
appears superior to 48 h. Since in preclinical models (28), shorter 
delays started to increase the doses delivered to normal tissues, 
this 24-h delay may be considered optimal. On the other hand, 
increasing the administered amount of TF2 could be problematic 
in terms of cost, even if there is no indication of tumor binding 
site saturation. Thus, to improve treatment efficacy, which was 
minimal in this optimization study with only two cases of disease 
stabilization for short periods of time, the injected activity should 
be increased for the second part of the study, which is planned 
with an activity escalation. Indeed, it was not expected that a 
single therapy cycle would be sufficient to deliver therapeutic 
doses that would show tumor shrinkage.
It has been shown that pretargeting performance strongly 
depends on the injected hapten to BsmAb molar ratio which 
should be kept as small as possible (1:20 or 1:40), as in this study. 
Then the hapten should be labeled to a high specific activity in 
order to target enough activity for therapy. This specific activity 
issue and the fact that tumor accretion is slower but significantly 
reversible make the use of shorter half-life and higher intrinsic 
toxicity radionuclides, such as yttrium-90, preferable to that of 
lutetium-177. The use of pairs of beta +  /beta-emitting radio-
nuclides (e.g., 86Y/90Y) could also be a promising theragnostic 
approach with a same distribution both for dosimetry imaging 
using immunoPET and therapy. Short half-life alpha-emitting 
radionuclides, such as bismuth-213 or astatine-211, could also 
be considered.
Finally, the immune response and the number of patient devel-
oping human antibody against TF2 were lower than described 
previously by Schoffelen and coworkers (16) in a population of 
patients with CRCs, and grade 2 acute infusion reactions were 
observed in one-third (7/21) of the patients during the second 
TF2 infusion. These immune reactions were attenuated by add-
ing antihistamine and corticosteroid premedications before the 
second TF2 infusion but did not disappear (immune response 
occurred in 2/5 premedicated patients). In our study, all patients 
were premedicated with an antihistamine and corticosteroid 
before each TF2 and peptide infusion, and none of them presented 
immune response symptoms. Moreover, Schoffelen and cowork-
ers (16) described an immunization rate of 50% with HAHA 
against TF2 detected in 11/21 patients as soon as 1 week after the 
FiGUrE 5 | normalized organ-absorbed doses per cohort assessed in the pretherapeutic (a) and therapeutic sessions (B). No significant statistical 
differences were found between groups. Abbreviations: WB, RL, LL, RK, LK, and RM stand, respectively, for whole body, right lung, left lung, right kidney, left kidney, 
and red marrow.
FiGUrE 6 | Tumor normalized-absorbed doses per cohort assessed in 
the pretherapeutic (a) and therapeutic sessions (B). Cohort I was 
significantly (p < 0.002) different from cohorts II and III.
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TaBlE 8 | Spearman tests for the correlation between organ-absorbed doses estimated during pretherapeutic and therapeutic sessionsa.
Spearman test 1 2 3 4 5 6 7 8
Rho 0.986 0.827 0.904 0.725 0.918 0.836 0.891 0.727
p-Value 0.000 0.031 0.000 0.007 0.000 0.003 0.001 0.015
aPatient 9 was not able to sustain therapeutic imaging session due to an altered condition.
second infusion gradually increasing in the follow-up period of 
8 weeks. HAHA against TF2 > 50 ng/mL was detected in only one 
of our eight patients evaluated, starting 1 month after the second 
TF2 infusion and gradually decreasing in the follow-up period 
of 3 months. If the use of an antiallergic premedication partially 
explained the absence of immune reactions at the time of second 
injection of TF2 in our study, this did not explain the lower number 
of patients developing HAHA. The explanation did not come from 
the TF2 injection schemes which were identical or from the TF2 
doses that were close. Our main hypothesis to explain this dis-
crepancy could reside in the different histological types of tumors 
included in the two studies. While in the two studies, patients have 
already been treated with multiple lines of treatment, relapsing 
lung cancer is often more aggressive than relapsing CRC. This 
could explain poorer general conditions (7/9 patients died in the 
year following the study) and thus a more compromised immune 
system. It may also be that metastatic NSCLC patients are more 
heavily pretreated with cytotoxic chemotherapy than patients 
with metastatic CRC, and this needs to be evaluated. In any case, 
the low immunogenicity and the low toxicity observed should 
offer the possibility of administering several courses of treatment 
to deliver tumor-killing irradiation levels.
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